Management of aboriginal and nonaboriginal people with chronic kidney disease in Quebec Quality-of-care indicators

• Published in: Canadian family physician 2012-02, Vol.58 (2), p.e107-e111
• Main Authors: Patapas, Jason Michael, Blanchard, Ana Chelene, Iqbal, Sameena, Vasilevsky, Murray, Dannenbaum, David
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anemia - complications; Anemia - drug therapy; Anemia - ethnology; Chronic illnesses; Cross-Sectional Studies; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - ethnology; Diabetes Mellitus, Type 2 - therapy; Erythropoietin - therapeutic use; Female; Health Care Surveys; Healthcare Disparities; Hematinics - therapeutic use; Humans; Indians, North American; Kidney diseases; Male; Middle Aged; Multivariate Analysis; Native North Americans; Proportional Hazards Models; Quality Indicators, Health Care; Quality of care; Quebec; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - ethnology; Renal Insufficiency, Chronic - therapy
• ISSN: 0008-350X; 1715-5258

To compare quality-of-care indicators for management of patients with chronic kidney disease (CKD) and type 2 diabetes among the James Bay Cree of Northern Quebec with those among residents of Montreal, Que. A cross-sectional survey using medical records from patients seen between 2002 and 2008. Predialysis clinics of the McGill University Health Centre in Montreal. Thirty Cree and 51 nonaboriginal patients older than 18 years of age with type 2 diabetes mellitus and estimated glomerular filtration rates of less than 60 mL/min/1.73 m2. Rates of anemia, iron deficiency, obesity, and renoprotective medication use among aboriginal and nonaboriginal patients. Overall, the Cree patients were younger (59 vs 68 years of age, P < .0035) and weighed more (101 vs 77 kg,P < .001). The 2 groups were prescribed medication to control blood pressure, lipids, and phosphate levels at similar rates, but the Cree patients were more likely to receive renoprotective agents (87% vs 65%, P = .04). Despite similar rates of erythropoietin supplementation, the Cree patients were at greater risk of anemia, with an adjusted risk ratio of 2.80 (95% CI 1.01 to 7.87). Cree patients with CKD were younger, weighed more, and were more likely to receive renoprotective agents. With the exception of the management of anemia, quality of CKD care was similar between the 2 groups.Anemia education for family physicians and continuous monitoring of quality indicators must be implemented in northern Quebec.